Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Lumito ABNGM:LUMITO +18.91%18 EBIT per Share is kr-16.35 as of Mar. 2026. GuruFocus rates NGM:LUMITO with a GF Score™ of 18/100. The stock has 2 warning signs investors should review. Among 164 Medical Diagnostics & Research companies, Lumito AB ranks better than 58.54% on this metric.
Lumito AB's EBIT per Share for the
three
months ended in Mar. 2026 was kr-2.32.
Its EBIT per Share for the trailing twelve months (TTM) ended in Mar. 2026 was kr-16.35.
During the past 3 years, the average EBIT per Share Growth Rate was 20.60% per year.
During the past 5 years, the average EBIT per Share Growth Rate was 20.60% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBIT per Share growth rate using EBIT per Share data.
The historical rank and industry rank for Lumito AB's EBIT per Share or its related term are showing as below:
NGM:LUMITO'
s 3-Year EBIT Growth Rate Range Over the Past 10 Years
Min: -58.3 Med: 12.3 Max: 22
Current: 20.6
During the past 9 years, the highest 3-Year average EBIT per Share Growth Rate of Lumito AB was 22.00% per year. The lowest was -58.30% per year. And the median was 12.30% per year.
NGM:LUMITO's 3-Year EBIT Growth Rate is ranked better than 58.54% of 164
companies
in the Medical Diagnostics & Research industry
Industry Median: 13.1
vs NGM:LUMITO: 20.60
Lumito AB's EBIT for the
three
months ended in Mar. 2026 was kr-10.23 Mil.
EBIT is a company's earnings before interest and tax expenses are deducted. It measures a company's profit generates from operating, ignoring tax burden and capital structure. As the tax expense are not deducted, EBIT is helpful when comparing companies in the same industry but with different tax situations. Also, the interest expense are included in EBIT, making it useful to compare companies that have high interest expenses due to large amount of debt.
Lumito AB EBIT per Share Related Terms
Lumito AB EBIT per Share Historical Data
* Premium members only.
The historical data trend for Lumito AB's EBIT per Share can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
EBIT per Share for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was kr-16.35
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Lumito AB (NGM:LUMITO) has a EBIT per Share of kr-16.35 as of Mar. 2026. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on Lumito AB and its competitors. According to the industry distribution chart, Lumito AB ranks #68 out of 164 companies in the Medical Diagnostics & Research industry, placing it in the top 41.5%.
Is Lumito AB's EBIT per Share too high?
Lumito AB's current EBIT per Share is kr-16.35. Based on the distribution chart, Lumito AB ranks #68 out of 164 companies in the Medical Diagnostics & Research industry, which is above the industry midpoint. Overall, Lumito AB has a GF Score™ of 18/100, reflecting its overall financial health beyond just this single metric.
How does Lumito AB's EBIT per Share compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Lumito AB ranks #68 out of 164 companies for EBIT per Share. This puts Lumito AB in the upper half of its industry. The industry median EBIT per Share is 13.10. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT per Share for a Medical Diagnostics & Research company?
The median EBIT per Share among Medical Diagnostics & Research companies is 13.10, based on 164 companies in the industry. Companies in the top quartile (top 25%) have a EBIT per Share significantly above this median, while those in the bottom quartile fall well below. However, EBIT per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT per Share mean?
A high EBIT per Share can signal that a stock is expensive relative to its fundamentals. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on Lumito AB and its competitors. For the Medical Diagnostics & Research industry, the median EBIT per Share is 13.10 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Lumito AB's current EBIT per Share is kr-16.35. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Lumito AB stock overvalued right now?
Lumito AB (NGM:LUMITO) has a current EBIT per Share of kr-16.35. The current EBIT per Share is kr-16.35. Lumito AB's overall GF Score™ is 18/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT per Share calculated?
EBIT per Share is calculated from a company's financial statements. For Lumito AB (NGM:LUMITO), the current EBIT per Share is kr-16.35 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Lumito AB is a Swedish company that specializes in the medical research and development of imaging technology for use in digital pathology. It has developed the next-generation tissue analysis system, based on upconverting nanoparticles (UCNPs). Lumito SCIZYS is a cutting-edge, high-sensitivity system combining labeling and imaging technologies to locate and measure biomarkers in tissue samples. The company holds a broad patent portfolio of three patent families. Lumito's solution enables quantitative and objective assessment of tissue samples, addressing a multitude of challenges in drug development and academic research.
18GF Score
Get the complete analysis for NGM:LUMITO
EBIT per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NGM:LUMITO has been successfully added to your 
